The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Aman U. Buzdar

Department of Breast Medical Oncology

University of Texas MD Anderson Cancer Center

1515 Holcombe Blvd

Box 1354

[email]@mdanderson.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 1354. 1999 - 2012
  • M.D. Anderson Cancer Center and US Oncology Research, Houston, and Baylor-Sammons Cancer Center and Texas Oncology, Dallas, USA. 2003

References

  1. Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer. Kelly, C.M., Green, M.C., Broglio, K., Thomas, E.S., Brewster, A.M., Valero, V., Ibrahim, N.K., Gonzalez-Angulo, A.M., Booser, D.J., Walters, R.S., Hunt, K.K., Hortobagyi, G.N., Buzdar, A.U. J. Clin. Oncol. (2012) [Pubmed]
  2. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Buzdar, A.U. Ann. Oncol. (2009) [Pubmed]
  3. Medical oncology: Endocrine-therapy-related symptoms and breast cancer. Buzdar, A.U. Nature Reviews. Clinical Oncology (2009) [Pubmed]
  4. Clinical experience with epothilones in patients with breast cancer. Buzdar, A.U. Clin. Breast Cancer (2008) [Pubmed]
  5. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer. Buzdar, A.U. Drugs. Today (2008) [Pubmed]
  6. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Buzdar, A.U., Coombes, R.C., Goss, P.E., Winer, E.P. Cancer (2008) [Pubmed]
  7. Preoperative chemotherapy treatment of breast cancer--a review. Buzdar, A.U. Cancer (2007) [Pubmed]
  8. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Buzdar, A.U., Valero, V., Ibrahim, N.K., Francis, D., Broglio, K.R., Theriault, R.L., Pusztai, L., Green, M.C., Singletary, S.E., Hunt, K.K., Sahin, A.A., Esteva, F., Symmans, W.F., Ewer, M.S., Buchholz, T.A., Hortobagyi, G.N. Clin. Cancer Res. (2007) [Pubmed]
  9. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Buzdar, A.U., Cuzick, J. Clin. Cancer Res. (2006) [Pubmed]
  10. Anastrozole for breast cancer: recent advances and ongoing challenges. Buzdar, A.U. Expert. Rev. Anticancer. Ther (2006) [Pubmed]
  11. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Buzdar, A.U., Robertson, J.F. Ann. Pharmacother (2006) [Pubmed]
  12. How rapidly do oncologists respond to clinical trial data?. Buzdar, A., Macahilig, C. Oncologist (2005) [Pubmed]
  13. TAS-108: a novel steroidal antiestrogen. Buzdar, A.U. Clin. Cancer Res. (2005) [Pubmed]
  14. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Buzdar, A.U., Ibrahim, N.K., Francis, D., Booser, D.J., Thomas, E.S., Theriault, R.L., Pusztai, L., Green, M.C., Arun, B.K., Giordano, S.H., Cristofanilli, M., Frye, D.K., Smith, T.L., Hunt, K.K., Singletary, S.E., Sahin, A.A., Ewer, M.S., Buchholz, T.A., Berry, D., Hortobagyi, G.N. J. Clin. Oncol. (2005) [Pubmed]
  15. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. Buzdar, A.U. Breast. Dis (2005) [Pubmed]
  16. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Buzdar, A.U., Vergote, I., Sainsbury, R. Breast. J (2004) [Pubmed]
  17. Current developments in hormonal therapy of breast cancer. Buzdar, A.U. Clin. Breast Cancer (2004) [Pubmed]
  18. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update. Buzdar, A.U. Clin. Breast Cancer (2004) [Pubmed]
  19. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer. Buzdar, A.U. Drugs. Today (2004) [Pubmed]
  20. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Buzdar, A.U. Clin. Cancer Res. (2003) [Pubmed]
  21. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. Buzdar, A., O'Shaughnessy, J.A., Booser, D.J., Pippen, J.E., Jones, S.E., Munster, P.N., Peterson, P., Melemed, A.S., Winer, E., Hudis, C. J. Clin. Oncol. (2003) [Pubmed]
  22. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. Buzdar, A. Clin. Breast Cancer (2003) [Pubmed]
  23. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Buzdar, A.U. Oncologist (2003) [Pubmed]
  24. Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer. Buzdar, A.U., Hortobagyi, G.N. Cancer Treat. Rev. (2003) [Pubmed]
  25. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview. Buzdar, A.U. J. Steroid Biochem. Mol. Biol. (2003) [Pubmed]
  26. Aromatase inhibitors in breast cancer therapy. Buzdar, A.U. Clin. Breast Cancer (2003) [Pubmed]
  27. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Buzdar, A.U., Singletary, S.E., Valero, V., Booser, D.J., Ibrahim, N.K., Rahman, Z., Theriault, R.L., Walters, R., Rivera, E., Smith, T.L., Holmes, F.A., Hoy, E., Frye, D.K., Manuel, N., Kau, S.W., McNeese, M.D., Strom, E., Thomas, E., Hunt, K., Ames, F., Berry, D., Hortobagyi, G.N. Clin. Cancer Res. (2002) [Pubmed]
  28. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Buzdar, A., Hayes, D., El-Khoudary, A., Yan, S., Lønning, P., Lichinitser, M., Gopal, R., Falkson, G., Pritchard, K., Lipton, A., Wolter, K., Lee, A., Fly, K., Chew, R., Alderdice, M., Burke, K., Eisenber, P. Breast Cancer Res. Treat. (2002) [Pubmed]
  29. New generation aromatase inhibitors--from the advanced to the adjuvant setting. Buzdar, A.U. Breast Cancer Res. Treat. (2002) [Pubmed]
  30. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Buzdar, A.U., Robertson, J.F., Eiermann, W., Nabholtz, J.M. Cancer (2002) [Pubmed]
  31. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen. Buzdar, A.U. Expert. Rev. Anticancer. Ther (2002) [Pubmed]
  32. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., Brady, C. J. Clin. Oncol. (2001) [Pubmed]
  33. A summary of second-line randomized studies of aromatase inhibitors. Buzdar, A.U. J. Steroid Biochem. Mol. Biol. (2001) [Pubmed]
  34. Tamoxifen's clinical applications: old and new. Buzdar, A.U. Arch. Fam. Med (2000) [Pubmed]
  35. Exemestane in advanced breast cancer. Buzdar, A. Anticancer. Drugs (2000) [Pubmed]
  36. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. Buzdar, A.U., Singletary, S.E., Theriault, R.L., Booser, D.J., Valero, V., Ibrahim, N., Smith, T.L., Asmar, L., Frye, D., Manuel, N., Kau, S.W., McNeese, M., Strom, E., Hunt, K., Ames, F., Hortobagyi, G.N. J. Clin. Oncol. (1999) [Pubmed]
 
WikiGenes - Universities